ANNORA PHARMA PRIVATE LIMITED
PharmaANNORA PHARMA PRIVATE LIMITED is a pharmaceutical company with 3 FDA-approved products.
ANNORA PHARMA PRIVATE LIMITED's Key Drugs
ANNORA PHARMA PRIVATE LIMITED's core commercial portfolio centers on SITAGLIPTIN AND METFORMIN HYDROCHLORIDE — its most strategically important drugs approved in the last 15 years.
ANNORA PHARMA PRIVATE LIMITED's Recent FDA Approvals
New NDA/BLA approvals for ANNORA PHARMA PRIVATE LIMITED over the last two years — novel drugs only, excluding generics and label supplements.
ANNORA PHARMA PRIVATE LIMITED's Therapeutic Areas
Disease areas where ANNORA PHARMA PRIVATE LIMITED has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ANNORA PHARMA PRIVATE LIMITED Pipeline Snapshot
Active clinical trials for ANNORA PHARMA PRIVATE LIMITED across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SITAGLIPTIN AND METFORMIN HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 6